1.
|
18 p, 2.5 MB |
The EHA Research Roadmap : Malignant Lymphoid Diseases
/
Dreyling, Martin (LMU Hospital (Alemanya)) ;
André, Marc (Université Catholique de Louvain (bèlgica)) ;
Gökbuget, Nicola (Goethe University (Alemanya)) ;
Tilly, Hervé (Centre Henri Becquerel and Université de Rouen (França)) ;
Jerkeman, Mats (Skåne University and Lund University (Suècia)) ;
Gribben, John (Queen Mary University of London (Regne Unit)) ;
Ferreri, Andrés (IRCCS San Raffaele Scientific Institute (Itàlia)) ;
Morel, Pierre (CHU Amiens Picardie (França)) ;
Stilgenbauer, Stephan (Universität Ulm (Alemanya)) ;
Fox, Christopher (University of Nottingham (Regne Unit)) ;
Maria Ribera, José (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Zweegman, Sonja (Amsterdam UMC (Països Baixos)) ;
Aurer, Igor (University of Zagreb (Zagreb)) ;
Bödör, Csaba (Semmelweis University (Hongria)) ;
Burkhardt, Birgit (Pädiatrische Hämatologie und Onkologie (Alemanya)) ;
Buske, Christian (University Hospital of Ulm (Alemanya)) ;
Dollores Caballero, Maria (El Instituto de Investigación Biomédica de Salamanca (Salamanca, Espanya)) ;
Campo, Elias (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Chapuy, Bjoern (Berlin Institute of Health (Alemanya)) ;
Davies, Andrew (University of Southampton (Regne Unit)) ;
de Leval, Laurence (Lausanne University Switzerland (Suïssa)) ;
Doorduijn, Jeanette (University Medical Center Rotterdam the Netherlands (Països Baixos)) ;
Federico, Massimo (GVM Care & Research (Itàlia)) ;
Gaulard, Philippe (Hôpital Henri Mondor (França)) ;
Gay, Francesca (AOU Città Della Salute e Della Scienza (Itàlia)) ;
Ghia, Paolo (IRCCS Ospedale San Raffaele (Itàlia)) ;
Grønbæk, Kirsten (University of Copenhagen (Dinamarca)) ;
Goldschmidt, Hartmut (University Hospital Heidelberg (Alemanya)) ;
Kersten, Marie-Jose (Cancer Center Amsterdam and LYMMCARE the Netherlands (Països Baixos)) ;
Kiesewetter, Barbara (Medical University of Vienna (Àustria)) ;
Landman-Parker, Judith (Sorbonne Université APHP/hôpital A Trousseau (França)) ;
Le Gouill, Steven (Clinique du Centre Hospitalier Universitaire (CHU) de Nantes (França)) ;
Lenz, Georg (Medical University Hospital Münster (Alemanya)) ;
Leppä, Sirpa (Helsinki University Hospital Comprehensive Cancer Centre Finland (Finlandia)) ;
López Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ;
Macintyre, Elizabeth (Assistance Publique-Hôpitaux de Paris (França)) ;
Mantega, Maria Victoria Mateos (Universidad de Salamanca (Salamanca, Espanya)) ;
Moreau, Philippe (University Hospital Hotel-Dieu (França)) ;
Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Nadel, Bertrand (Aix Marseille Univ (França)) ;
Okosun, Jessica (Queen Mary University of London (Regne Unit)) ;
Owen, Roger (St James's Institute of Oncology (Regne Unit)) ;
Pospisilova, Sarka (University Hospital Brno (Txèquia)) ;
Pott, Christiane (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Robak, Tadeusz (Medical University of Lodz (Polònia)) ;
Spina, Michelle (National Cancer Institute (Itàlia)) ;
Stamatopoulos, Kostas (Centre for Research and Technology Hellas Greece (Grècia)) ;
Stary, Jan (Charles University Prague University Hospital Czech Republic (Txèquia)) ;
Tarte, Karin (Immunology and Cell Therapy Lab at Rennes University Hospital (França)) ;
Tedeschi, Allessandra (Niguarda Hospital Milano (Itàlia)) ;
Thieblemont, Catherine (Assistance Publique-Hôpitaux de Paris (França)) ;
Trappe, Ralf Ulrich (DIAKO Hospital Bremen (Alemanya)) ;
Trümper, Lorenz H. (University Medicine Goettingen (Alemanya)) ;
Salles, Gilles (Weill Cornell Medicine (Estats Units)) ;
Universitat Autònoma de Barcelona
2022 - 10.1097/HS9.0000000000000726
HemaSphere, Vol. 6 (may 2022)
|
|
2.
|
10 p, 809.5 KB |
The MUK five protocol : a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma
/
Brown, Sarah (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Hinsley, Samantha (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Ballesteros Silva, Mónica Patricia (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ;
Bourne, Sue (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
McGarry, Paul (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Sherratt, Debbie (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Flanagan, Louise (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Gregory, Walter (Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK) ;
Cavenagh, Jamie (St Bartholomew's Hospital (Regne Unit)) ;
Owen, Roger (HMDS Laboratory, St James's University Hospital, Leeds, UK) ;
Williams, Cathy (Centre for Clinical Haematology, Nottingham University Hospitals, Nottingham, UK) ;
Kaiser, Martin (The Institute of Cancer Research, Sutton, UK) ;
Low, Eric (Myeloma UK, Edinburgh, UK) ;
Yong, Kwee (UCL Cancer Institute (Londres, Regne Unit))
Multiple myeloma is a plasma cell tumour with an annual incidence in the UK of approximately 40-50 per million i. e. about 4500 new cases per annum. The triple combination cyclophosphamide, bortezomib (Velcade®) and dexamethasone (CVD) is an effective regimen at relapse and has emerged in recent years as the standard therapy at first relapse in the UK. [...]
2016 - 10.1186/s12878-016-0053-9
BMC Hematology, Vol. 16 (may 2016)
|
|